Kura Oncology, Inc. (NASDAQ:KURA) has been given an average recommendation of “Buy” by the seven research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $18.33.

KURA has been the subject of several analyst reports. Oppenheimer Holdings, Inc. set a $18.00 target price on Kura Oncology and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Citigroup Inc. set a $13.00 target price on Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Leerink Swann restated an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Finally, ValuEngine upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Friday, September 8th.

Shares of Kura Oncology (KURA) traded up $0.20 during trading on Wednesday, hitting $15.75. The stock had a trading volume of 157,623 shares, compared to its average volume of 288,800. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48. Kura Oncology has a fifty-two week low of $4.72 and a fifty-two week high of $16.75.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). equities analysts expect that Kura Oncology will post -1.45 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Analysts Set Kura Oncology, Inc. (KURA) Target Price at $17.67” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/18/analysts-set-kura-oncology-inc-kura-target-price-at-17-67.html.

Hedge funds have recently modified their holdings of the company. State of Wisconsin Investment Board acquired a new position in shares of Kura Oncology during the second quarter worth approximately $102,000. Rhumbline Advisers acquired a new position in shares of Kura Oncology during the second quarter worth approximately $131,000. New York State Common Retirement Fund acquired a new position in shares of Kura Oncology during the second quarter worth approximately $142,000. OxFORD Asset Management LLP acquired a new position in shares of Kura Oncology during the second quarter worth approximately $217,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Kura Oncology during the second quarter worth approximately $226,000. Institutional investors own 39.11% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.